Editas Medicine GAAP EPS of -$0.63 misses by $0.25, revenue of $3.58M beats by $1.78M

* Editas Medicine press release [https://seekingalpha.com/pr/20198540-editas-medicine-announces-second-quarter-2025-results-and-business-updates] (NASDAQ:EDIT [https://seekingalpha.com/symbol/EDIT]): Q2 GAAP EPS of -$0.63 misses by $0.25.
* Revenue of $3.58M (+602.0% Y/Y) beats by $1.78M.

MORE ON EDITAS MEDICINE

* Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible [https://seekingalpha.com/article/4806365-editas-medicine-primed-for-an-unlikely-comeback-its-not-impossible]
* Gene editors steady despite latest leadership shake-up at FDA [https://seekingalpha.com/news/4460031-gene-editing-stocks-gain-amid-fda-latest-leadership-change]
* RFK Jr. looks to fast track rare disease drug approvals (updated) [https://seekingalpha.com/news/4456197-rfk-jr-looks-fast-track-rare-disease-drug-approvals]
* Seeking Alpha’s Quant Rating on Editas Medicine [https://seekingalpha.com/symbol/EDIT/ratings/quant-ratings]
* Historical earnings data for Editas Medicine [https://seekingalpha.com/symbol/EDIT/earnings]